Clinical Trial Update: A Study of Gemzar, Taxotere, and Xeloda for Adjuvant Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating gemcitabine, docetaxel, and capecitabine as adjuvant therapy for pancreatic cancer has completed enrollment with results posted in 2016…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemzar (gemcitabine)
• Taxotere (docetaxel)
• Xeloda (capecitabine)

Snippet

Sponsor: Columbia University | Conditions: Pancreatic Cancer | Phase 2 | Status: COMPLETED | Results posted: 2016-06-22